Susquehanna International Group, LLP Mereo Biopharma Group PLC Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.45 - $4.87 $171,120 - $241,552	49,600 Added 46.14%	157,100 $645,000
Q2 2024 Aug 15, 2024	SELL	$2.58 - $4.25 $147,834 - $243,525	-57,300 Reduced 34.77%	107,500 $387,000
Q1 2024 May 07, 2024	BUY	$2.3 - $4.05 $331,430 - $583,605	144,100 Added 696.14%	164,800 $543,000
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $8,211 - $16,698	6,900 Added 50.0%	20,700 $47,000
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $7,474 - $10,855	-6,500 Reduced 32.02%	13,800 $17,000
Q2 2023 Aug 11, 2023	BUY	$0.79 - $1.43 $16,037 - $29,029	20,300 New	20,300 $26,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $23,042 - $48,613	28,100 Added 33.98%	110,800 $95,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $440M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.